Roivant Sciences Ltd. (ROIV)
NASDAQ
Key stats Fiscal year 2026
Income statement
- Revenue
- 8,260,000 -71.6%
- Net income
- -299,771,000
- Operating income
- -515,068,000
- Earnings per share
- -0.43
- R&D expense
- 681,812,000
Growth and profitability
- Operating margin
- -6,235.69
- Net margin
- -3,629.19
- Return on equity
- -6.62
- Return on assets
- -5.25
- Free cash flow margin
- -9,183.51
Balance sheet
- Total assets
- 5,708,687,000
- Total liabilities
- 416,275,000
- Shareholders' equity
- 4,527,370,000
- Cash and equivalents
- 1,419,232,000
- Current ratio
- 18.37
Cash flow and ratios
- Operating cash flow
- -750,349,000
- Free cash flow
- -758,558,000
Shareholder returns
- Shares outstanding
- 724,561,460
- Book value per share
- 6.25
Company information
- Headquarters
- London
- Exchange
- NASDAQ
- Fiscal year end
- 03-31
- Industry (SEC)
- Pharmaceutical Preparations
Fiscal year end: · Source: SEC EDGAR
Roivant Sciences Ltd. trades on NASDAQ under the ticker symbol ROIV. This page brings together its price chart, company profile, key financial figures and technical indicators.